Technology transfer / Localization · Africa · Announced 1 Jan 2026
Minhai Biotechnology → VACSERA
Technology transfer / Localization deal between Minhai Biotechnology (China) and VACSERA (Egypt), covering Vaccines, announced 1 Jan 2026.
Parties: Minhai Biotechnology (China) → VACSERA (Egypt)
- Deal type
- Technology transfer / Localization
- Value
- Not stated
- Territory
- Egypt (national immunisation); stated intent to export to regional & African markets
- Therapeutic area
- Vaccines
- Asset
- Vaccines — infectious disease (paediatric immunisation)
- Announced
- 1 Jan 2026
Our analysis
Why it matters
A high-value conjugate vaccine, localized. PCV13 is not a simple vaccine; pneumococcal conjugate vaccines are among the more technically demanding and expensive childhood immunisations , historically dominated by a small number of Western manufacturers.
Localizing PCV13 on VACSERA's lines — using Minhai's technology via GenVax — would let Egypt meet its national immunisation requirements domestically rather than importing, and management explicitly framed it as paving the way for exports to regional and African markets.
The full analysis is free to read with a work email on this page.
Source: Daily News Egypt